ThirtyFiveBio
ThirtyFiveBio are developing a gut epithelial shield for patients with ulcerative colitis. Protecting the gut epithelium by reducing epithelial dysfunction and damage seen in patients holds the promise of revolutionising outcomes for IBD patients and disrupting IBD treatment paradigms.
Developing a Gut Epithelial Shield for Patients With Colitis
ThirtyFiveBio are developing oral, small molecule GPR35 inhibitors. GPR35 inhibition protects gut epithelial cells under attack by inflammatory factors in colitis.
Current Progress
ThirtyFiveBio have developed a preclinical development candidate small molecule inhibitor of GPR35.
What’s Next
We are advancing through late preclinical activities towards clinical proof-of-mechanism in 2028.
